{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:27:34Z","timestamp":1782894454676,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,30]]},"DOI":"10.7759\/cureus.111855","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:26:00Z","timestamp":1782887160000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Drug Retention and Safety of Ustekinumab in Patients With Inflammatory Bowel Disease in Qatar: A Retrospective Cohort Study"],"prefix":"10.7759","author":[{"given":"Abdulwahab","family":"Hamid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Badi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Ayash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahaya","family":"Bensuleiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souraia","family":"Mezhoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Abderahim","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia","family":"Battah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munir","family":"Abu Ageila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdurahman","family":"Kday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneera","family":"Almohannadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng SC","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, et al.. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017, 390:2769-78. 10.1016\/s0140-6736(17)32448-0","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2024.0909","article-title":"Inflammatory bowel disease burden in the Middle East and North Africa Region: a comprehensive analysis of incidence, prevalence, and mortality from 1990-2019","volume":"37","author":"Alsakarneh S","year":"2024","unstructured":"Alsakarneh S, Ahmed M, Jaber F, et al.. Inflammatory bowel disease burden in the Middle East and North Africa Region: a comprehensive analysis of incidence, prevalence, and mortality from 1990-2019. Ann Gastroenterol. 2024, 37:527-35. 10.20524\/aog.2024.0909","journal-title":"Ann Gastroenterol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare13233104","article-title":"The burden of inflammatory bowel disease in Gulf Cooperation Council countries from 1990 to 2021 with forecasting projections to 2030: a Global Burden of Disease Study","volume":"13","author":"Alsaif AK","year":"2025","unstructured":"Alsaif AK, Alnajjar JS, Al-Harbi FA, et al.. The burden of inflammatory bowel disease in Gulf Cooperation Council countries from 1990 to 2021 with forecasting projections to 2030: a Global Burden of Disease Study. Healthcare (Basel). 2025, 13:3104. 10.3390\/healthcare13233104","journal-title":"Healthcare (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000518003","article-title":"Incidence, prevalence, and clinical epidemiology of inflammatory bowel disease in the Arab world: a systematic review and meta-analysis","volume":"6","author":"Mosli M","year":"2021","unstructured":"Mosli M, Alawadhi S, Hasan F, Abou Rached A, Sanai F, Danese S. Incidence, prevalence, and clinical epidemiology of inflammatory bowel disease in the Arab world: a systematic review and meta-analysis. Inflamm Intest Dis. 2021, 6:123-31. 10.1159\/000518003","journal-title":"Inflamm Intest Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.88","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review","volume":"104","author":"Gisbert JP","year":"2009","unstructured":"Gisbert JP, Pan\u00e9s J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009, 104:760-7. 10.1038\/ajg.2008.88","journal-title":"Am J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.579","article-title":"The natural history of adult Crohn's disease in population-based cohorts","volume":"105","author":"Peyrin-Biroulet L","year":"2010","unstructured":"Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010, 105:289-97. 10.1038\/ajg.2009.579","journal-title":"Am J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt B","year":"2023","unstructured":"Verstockt B, Salas A, Sands BE, Abraham C, Leibovitzh H, Neurath MF, Vande Casteele N. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2023, 20:433-46. 10.1038\/s41575-023-00768-1","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan BG","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, et al.. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016, 375:1946-60. 10.1056\/NEJMoa1602773","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands BE","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, et al.. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019, 381:1201-14. 10.1056\/NEJMoa1900750","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa236","article-title":"Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis of results from phase 2\/3 studies","volume":"27","author":"Sandborn WJ","year":"2021","unstructured":"Sandborn WJ, Feagan BG, Danese S, et al.. Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis of results from phase 2\/3 studies. Inflamm Bowel Dis. 2021, 27:994-1007. 10.1093\/ibd\/izaa236","journal-title":"Inflamm Bowel Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz119","article-title":"Ustekinumab for Crohn's disease: results of the ICC Registry, a nationwide prospective observational cohort study","volume":"14","author":"Biemans VBC","year":"2020","unstructured":"Biemans VBC, van der Meulen-de Jong AE, van der Woude CJ, et al.. Ustekinumab for Crohn's disease: results of the ICC Registry, a nationwide prospective observational cohort study. J Crohns Colitis. 2020, 14:33-45.  10.1093\/ecco-jcc\/jjz119","journal-title":"J Crohns Colitis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02611-0","article-title":"Real-world persistence of ustekinumab in the treatment of inflammatory bowel disease","volume":"40","author":"Bressler B","year":"2023","unstructured":"Bressler B, Jones J, In TS, Lan T, Iconaru C, Marshall JK. Real-world persistence of ustekinumab in the treatment of inflammatory bowel disease. Adv Ther. 2023, 40:4421-39. 10.1007\/s12325-023-02611-0","journal-title":"Adv Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-024-03577-1","article-title":"Superior persistence of ustekinumab compared to anti-TNF in vedolizumab-experienced inflammatory bowel diseases patients: a real-world cohort study","volume":"24","author":"Chiu HY","year":"2024","unstructured":"Chiu HY, Kuo CJ, Lai MW, et al.. Superior persistence of ustekinumab compared to anti-TNF in vedolizumab-experienced inflammatory bowel diseases patients: a real-world cohort study. BMC Gastroenterol. 2024, 24:483. 10.1186\/s12876-024-03577-1","journal-title":"BMC Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2025-002034","article-title":"Utilisation and real-world effectiveness of advanced therapies for inflammatory bowel disease in Middle Eastern populations: a systematic review","volume":"12","author":"Quraishi MN","year":"2025","unstructured":"Quraishi MN, Alahmad MA, Sharara AI, Trivedi PJ, Al-Bawardy B, Alrubaiy L. Utilisation and real-world effectiveness of advanced therapies for inflammatory bowel disease in Middle Eastern populations: a systematic review. BMJ Open Gastroenterol. 2025, 12:e002034. 10.1136\/bmjgast-2025-002034","journal-title":"BMJ Open Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.70311","article-title":"Pregnancy outcomes and disease activity in women with inflammatory bowel disease in Qatar: a retrospective cohort study","volume":"10","author":"Joudah AI","year":"2026","unstructured":"Joudah AI, Hamid A, Al-Dahshan A, et al.. Pregnancy outcomes and disease activity in women with inflammatory bowel disease in Qatar: a retrospective cohort study. JGH Open. 2026, 10:e70311. 10.1002\/jgh3.70311","journal-title":"JGH Open"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(07)61602-x","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm E","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, et al.. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007, 370:1453-57. 10.1016\/s0140-6736(07)61602-x","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19 Suppl A","author":"Silverberg MS","year":"2005","unstructured":"Silverberg MS, Satsangi J, Ahmad T, et al.. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005, 19 Suppl A:5A-36A. 10.1155\/2005\/269076","journal-title":"Can J Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-021-06932-4","article-title":"Effectiveness and safety of ustekinumab in inflammatory bowel disease: a systematic review and meta-analysis","volume":"67","author":"Honap S","year":"2022","unstructured":"Honap S, Meade S, Ibraheim H, Irving PM, Jones MP, Samaan MA. Effectiveness and safety of ustekinumab in inflammatory bowel disease: a systematic review and meta-analysis. Dig Dis Sci. 2022, 67:1018-35. 10.1007\/s10620-021-06932-4","journal-title":"Dig Dis Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab357","article-title":"Long-term real-world effectiveness and safety of ustekinumab in Crohn\u2019s disease patients: the SUSTAIN Study","volume":"28","author":"Chaparro M","year":"2022","unstructured":"Chaparro M, Baston-Rey I, Fern\u00e1ndez-Salgado E, et al.. Long-term real-world effectiveness and safety of ustekinumab in Crohn\u2019s disease patients: the SUSTAIN Study. Inflamm Bowel Dis. 2022, 28:1725-36. 10.1093\/ibd\/izab357","journal-title":"Inflamm Bowel Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-022-07501-z","article-title":"Ustekinumab is associated with real-world long-term effectiveness and improved health-related quality of life in Crohn\u2019s disease","volume":"68","author":"Forss A","year":"2023","unstructured":"Forss A, Clements M, Myrelid P, et al.. Ustekinumab is associated with real-world long-term effectiveness and improved health-related quality of life in Crohn\u2019s disease. Dig Dis Sci. 2023, 68:65-76. 10.1007\/s10620-022-07501-z","journal-title":"Dig Dis Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2024.00118","article-title":"Persistence of advanced therapies in patients with inflammatory bowel disease: retrospective cohort study using a large healthcare claims database in Japan","volume":"23(3)","author":"Matsuoka K","year":"2025","unstructured":"Matsuoka K, Nakajo K, Kawamura S, et al.. Persistence of advanced therapies in patients with inflammatory bowel disease: retrospective cohort study using a large healthcare claims database in Japan. Intest Res. 2025, 23(3):358-71. 10.5217\/ir.2024.00118","journal-title":"Intest Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2023.2278427","article-title":"Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort","volume":"59","author":"Iborra M","year":"2024","unstructured":"Iborra M, Ferreiro-Iglesias R, Maria Dolores MA, et al.. Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort. Scand J Gastroenterol. 2024, 59:260-8. 10.1080\/00365521.2023.2278427","journal-title":"Scand J Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otae024","article-title":"Effectiveness and persistency of ustekinumab treatment for ulcerative colitis: a Phoenix retrospective cohort study","volume":"6","author":"Ando K","year":"2024","unstructured":"Ando K, Fujiya M, Ueno N, et al.. Effectiveness and persistency of ustekinumab treatment for ulcerative colitis: a Phoenix retrospective cohort study. Crohns Colitis 360. 2024, 6:otae024. 10.1093\/crocol\/otae024","journal-title":"Crohns Colitis 360"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16436","article-title":"Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study","volume":"54","author":"Ko Y","year":"2021","unstructured":"Ko Y, Paramsothy S, Yau Y, Leong RW. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. Aliment Pharmacol Ther. 2021, 54:292-301. 10.1111\/apt.16436","journal-title":"Aliment Pharmacol Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1159\/000531497","article-title":"Real-world effectiveness and risk factors for discontinuation of ustekinumab in ulcerative colitis","volume":"8","author":"Uchida G","year":"2023","unstructured":"Uchida G, Nakamura M, Yamamura T, et al.. Real-world effectiveness and risk factors for discontinuation of ustekinumab in ulcerative colitis. Inflamm Intest Dis. 2023, 8:60-8. 10.1159\/000531497","journal-title":"Inflamm Intest Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-year efficacy and safety of ustekinumab treatment in Crohn\u2019s disease: the IM-UNITI trial","volume":"20","author":"Sandborn WJ","year":"2022","unstructured":"Sandborn WJ, Rebuck R, Wang Y, et al.. Five-year efficacy and safety of ustekinumab treatment in Crohn\u2019s disease: the IM-UNITI trial. Clin Gastroenterol Hepatol. 2022, 20:578-90.e4. 10.1016\/j.cgh.2021.02.025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae013","article-title":"Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis through 5 years in Crohn\u2019s disease and 4 years in ulcerative colitis","volume":"18","author":"Ghosh S","year":"2024","unstructured":"Ghosh S, Feagan BG, Ott E, et al.. Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis through 5 years in Crohn\u2019s disease and 4 years in ulcerative colitis. J Crohns Colitis. 2024, 18:1091-101. 10.1093\/ecco-jcc\/jjae013","journal-title":"J Crohns Colitis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-025-03676-z","article-title":"Safety assessment of ustekinumab in inflammatory bowel disease: a real-world analysis based on the FDA Adverse Event Reporting System (FAERS)","volume":"31","author":"Xu L","year":"2025","unstructured":"Xu L, Huang Z, Chen G, Sun C, Yu Y, Gao S. Safety assessment of ustekinumab in inflammatory bowel disease: a real-world analysis based on the FDA Adverse Event Reporting System (FAERS). Eur J Med Res. 2025, 31:93. 10.1186\/s40001-025-03676-z","journal-title":"Eur J Med Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad131","article-title":"Assessing progression of biologic therapies based on smoking status in patients with Crohn's disease","volume":"30","author":"Alizadeh M","year":"2024","unstructured":"Alizadeh M, Ali O, Cross RK. Assessing progression of biologic therapies based on smoking status in patients with Crohn's disease. Inflamm Bowel Dis. 2024, 30:788-94. 10.1093\/ibd\/izad131","journal-title":"Inflamm Bowel Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/499816-real-world-drug-retention-and-safety-of-ustekinumab-in-patients-with-inflammatory-bowel-disease-in-qatar-a-retrospective-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:26:01Z","timestamp":1782887161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/499816-real-world-drug-retention-and-safety-of-ustekinumab-in-patients-with-inflammatory-bowel-disease-in-qatar-a-retrospective-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.111855","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}